Identification of Circulating MicroRNA Signatures for Breast Cancer Detection
-
- Maurice Chan
- Authors' Affiliations: 1Division of Medical Sciences and 2Department of Surgical Oncology, National Cancer Centre; 3Blood Supply Division, Blood Services Group, Health Sciences Authority, Singapore; and Departments of 4General Surgery and 5Pathology, Singapore General Hospital, Singapore
-
- Chiew Suan Liaw
- Authors' Affiliations: 1Division of Medical Sciences and 2Department of Surgical Oncology, National Cancer Centre; 3Blood Supply Division, Blood Services Group, Health Sciences Authority, Singapore; and Departments of 4General Surgery and 5Pathology, Singapore General Hospital, Singapore
-
- Shen Mo Ji
- Authors' Affiliations: 1Division of Medical Sciences and 2Department of Surgical Oncology, National Cancer Centre; 3Blood Supply Division, Blood Services Group, Health Sciences Authority, Singapore; and Departments of 4General Surgery and 5Pathology, Singapore General Hospital, Singapore
-
- Hwee Huang Tan
- Authors' Affiliations: 1Division of Medical Sciences and 2Department of Surgical Oncology, National Cancer Centre; 3Blood Supply Division, Blood Services Group, Health Sciences Authority, Singapore; and Departments of 4General Surgery and 5Pathology, Singapore General Hospital, Singapore
-
- Chow Yin Wong
- Authors' Affiliations: 1Division of Medical Sciences and 2Department of Surgical Oncology, National Cancer Centre; 3Blood Supply Division, Blood Services Group, Health Sciences Authority, Singapore; and Departments of 4General Surgery and 5Pathology, Singapore General Hospital, Singapore
-
- Aye Aye Thike
- Authors' Affiliations: 1Division of Medical Sciences and 2Department of Surgical Oncology, National Cancer Centre; 3Blood Supply Division, Blood Services Group, Health Sciences Authority, Singapore; and Departments of 4General Surgery and 5Pathology, Singapore General Hospital, Singapore
-
- Puay Hoon Tan
- Authors' Affiliations: 1Division of Medical Sciences and 2Department of Surgical Oncology, National Cancer Centre; 3Blood Supply Division, Blood Services Group, Health Sciences Authority, Singapore; and Departments of 4General Surgery and 5Pathology, Singapore General Hospital, Singapore
-
- Gay Hui Ho
- Authors' Affiliations: 1Division of Medical Sciences and 2Department of Surgical Oncology, National Cancer Centre; 3Blood Supply Division, Blood Services Group, Health Sciences Authority, Singapore; and Departments of 4General Surgery and 5Pathology, Singapore General Hospital, Singapore
-
- Ann Siew-Gek Lee
- Authors' Affiliations: 1Division of Medical Sciences and 2Department of Surgical Oncology, National Cancer Centre; 3Blood Supply Division, Blood Services Group, Health Sciences Authority, Singapore; and Departments of 4General Surgery and 5Pathology, Singapore General Hospital, Singapore
Description
<jats:title>Abstract</jats:title> <jats:p>Purpose: There is a quest for novel noninvasive diagnostic markers for the detection of breast cancer. The goal of this study is to identify circulating microRNA (miRNA) signatures using a cohort of Asian Chinese patients with breast cancer, and to compare miRNA profiles between tumor and serum samples.</jats:p> <jats:p>Experimental Design: miRNA from paired breast cancer tumors, normal tissue, and serum samples derived from 32 patients were comprehensively profiled using microarrays or locked nucleic acid real-time PCR panels. Serum samples from healthy individuals (n = 22) were also used as normal controls. Significant serum miRNAs, identified by logistic regression, were validated in an independent set of serum samples from patients (n = 132) and healthy controls (n = 101).</jats:p> <jats:p>Results: The 20 most significant miRNAs differentially expressed in breast cancer tumors included miRNA (miR)-21, miR-10b, and miR-145, previously shown to be dysregulated in breast cancer. Only 7 miRNAs were overexpressed in both tumors and serum, suggesting that miRNAs may be released into the serum selectively. Interestingly, 16 of the 20 most significant miRNAs differentially expressed in serum samples were novel. MiR-1, miR-92a, miR-133a, and miR-133b were identified as the most important diagnostic markers, and were successfully validated; receiver operating characteristic curves derived from combinations of these miRNAs exhibited areas under the curves of 0.90 to 0.91.</jats:p> <jats:p>Conclusion: The clinical use of miRNA signatures as a noninvasive diagnostic strategy is promising, but should be further validated for different subtypes of breast cancers. Clin Cancer Res; 19(16); 4477–87. ©2013 AACR.</jats:p>
Journal
-
- Clinical Cancer Research
-
Clinical Cancer Research 19 (16), 4477-4487, 2013-08-13
American Association for Cancer Research (AACR)
- Tweet
Details 詳細情報について
-
- CRID
- 1361418521341706752
-
- ISSN
- 15573265
- 10780432
-
- Data Source
-
- Crossref